In:
Thoracic Cancer, Wiley, Vol. 4, No. 4 ( 2013-11), p. 440-448
Abstract:
Phase II‐III trials in patients with untreated and previously treated locally advanced or non‐small cell lung cancer ( NSCLC) suggested that Endostar was able to enhance the effect of platinum‐based chemotherapy ( NP regimen) with tolerable adverse effects. Methods Four hundred and eighty six patients were randomized into two arms: study arm A : NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B : NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles. Results: Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P 〈 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in A rm A compared with 28.2%, 3.0%, and 6.6%, respectively, in A rm B (P 〉 0.05). There were two treatment related deaths in arm A and one in arm B (P 〉 0.05). The median overall survival was longer in arm A than in arm B (P 〈 0.0001). Conclusion: Long‐term follow‐up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.
Type of Medium:
Online Resource
ISSN:
1759-7706
,
1759-7714
DOI:
10.1111/tca.2013.4.issue-4
DOI:
10.1111/1759-7714.12050
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2559245-2
Permalink